NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10550778		
	Filing Date		2005-09-27		
	First Named Inventor	Jürg 2	Zumbrunn		
	Art Unit		1654		
	Examiner Name	Kosar	r, Andrew D.		
	Attorney Docket Number		753-54 PCT/US		

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear			
	1										
If you wisl	h to add	d additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite N	o Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1										
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*		Foreign Document Number ³			Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		т.	
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Τs			

| INFORMATION DISCLOSURE | Application Number | 10550778 | Filing Date | 2005-09-27 | Filing Date | 20

1 Matsuzak, Katsumi, et al., *Teteractions of an entimicrobial peptide, tachypiesan I, with lipid membranen*, Biochimica ed Biochrysica Acts, 1070, pp. 259-264 (1991) 2 Crista, Akra, et al., *Molecular Parameters for the Arti-Human Immunodelicinency Virus Activity of T22 (TTy51,2, Lyn7): Poppherensian, Hirokacu, et al., *Synthesis and Evaluation of Pseudopoptide Analogues of a Specific XXXR4 inhibitor, 1140. The Intention of an (E)-Alkere Depotide Inside the Edit-Tum Molety*, Biocoganic & Medicinal Chemistry Letters, Vol. 12, pp. 923-928 (2002). If you wish to not disclosing incompanies if persuant adsorption program and experience and exper	EXAMINER SIGNATURE							
Biophysica Acts, 1070, pp. 259-264 (1991) 2 Olaka, Akra, et al., "Nolecular Parameters for the Anti-Human Immunodeficiency Virus Activity of T22 ([Ty15], L.ys.7]; Polyphemusin (I)17, Biol. Pharm. Bull. 17(12), pp. 1693-1672 (1994) Tamararum, Hirokazu, et al., "Synthesis and Evaluation of Pseudopoptide Analogues of a Specific CXCR4 tribitor, 17 1407. The Immedian of Ing. Disklerch Depolitic bioster and the Bill Turn Molety." Biospania & Medicinal Chemistry 1 1407. The Immedian of Ing. Disklerch Depolitic bioster and the Bill Turn Molety." Biospania & Medicant Chemistry	If you wish to add additional non-patent literature document citation information please click the Add button Add							
Bophysica Acta, 1070, pp. 259-264 (1991) Clarka, Akra, et al., "Molecular Parameters for the Anti-Human Immunodeficiency Virsa Activity of T22 ([Ty/5,12, Lyx7]) Clarka, Akra, et al., "Molecular Parameters for the Anti-Human Immunodeficiency Virsa Activity of T22 ([Ty/5,12, Lyx7])	3	T140: The Insertion of an (E)-Alkene Dipeptide Isoslere into the Bill'-Turn Molety', Bioorganic & Medicinal Chemistry						
	2							
	1		_					

Examiner Signature | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MEPE 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Table Kind Code of USPTO Patent Documents at wave <u>USPTO GOV</u> or MPEP 90.04. I Enter office that issued the document, by the two-letter code (WIPO Standard ST.3.). For <u>Upperson</u> patent document, by the two-letter code (WIPO Standard ST.3.). For <u>Upperson</u> patent document, and the second manufacture of the patent document.

Standard ST.3.1. For <u>Upperson</u> patent document under WIPO Standard ST.46 possible. I applicated to place a receive much process the patent document under WIPO Standard ST.46 possible. I applicated to place a receive much process the patent document under the pate